Lung: Non Small Cell Advanced, Tissue Repository Clinical Trials
Back to Oncology/Cancer Clinical Trials Main Page
CPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period | |
|---|---|---|---|---|
| Principal Investigator: Ari Baron, MD Contact: Zeena Salman 415-600-3241 Email SalmanZ@cpmcri.org | A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV) (ATTRACT-2) Visit the Metastatic Non-Small Cell Lung Cancer study on ClinicalTrials.gov. | Subjects who have been diagnosed with advanced non-small cell lung cancer that may or may not have spread to other organs in your body | Open | |
| Principal Investigator: Alan Kramer, MD Contact: Ron Frianeza 415-600-3027 Email frianer@cpmcri.org | A Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Aptium 05LUN01 Visit the Advanced Non-Small Cell Lung Cancer study on ClinicalTrials.gov. | Subjects who have stage IIIB or stage IV (metastatic) non-small cell lung cancer (NSCLC) and have received treatment with one prior platinum based chemotherapy | Open | |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Never Smokers With Stage IIIB and IV Primary Lung Adenocarcinomas. SWOG S0636 Visit the SWOG S0636 study on ClinicalTrials.gov. | Subjects with lung cancer who have never smoked | Open | |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenoBAC). SWOG S0635 Visit the SWOG S0635 study on ClinicalTrials.gov. | Subjects with Stage IIIB and IV Bronchioloalveolar Carcinomba (BAC) and Adenocarcinma with BAC features (AdenoBAC) | Open | |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer. RTOG0617 Visit the Non-Small Cell Lung Cancer study on ClinicalTrials.gov. | Subjects with histologically or cytologically proven diagnosis of Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer (NSCLC) | Open | |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely resected Stage IB-IIIA Non Small Cell Lung Cancer (NSCLC). ECOG 1505 Visit the Resected Stage IB-IIIA study on ClinicalTrials.gov. | Subjects who must have undergone complete resection of their Non Small Cell Lung Cancer (NSCLC) | Open | |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Lung Cancer Specimen Repository Protocol, Ancillary. SWOG S9925 Visit the Lung Cancer Specimen Repository study on ClinicalTrials.gov. | Subjects with lung cancer | Open |
updated: 1/15/10
Back to top